Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

Annals of Oncology

Volumn 22, Issue 9, 2011, Pages 2036-2041

  Zweifel, M ^a   Jayson, G C ^b   Reed, N S ^c   Osborne, R ^d   Hassan, B ^e   Ledermann, J ^f   Shreeves, G ^a   Poupard, L ^a   Lu, S P ^g   Balkissoon, J ^g   Chaplin, D J ^g   Rustin, G J S ^a  

^a MOUNT VERNON CANCER CENTRE   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^d POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

^g OXiGENE Inc   (United States)

Author keywords

Carboplatin; Combretastatin; Ovarian cancer; Paclitaxel; Phase II trial; Vascular disrupting agent

Indexed keywords

AMLODIPINE; CA 125 ANTIGEN; CA 19-9 ANTIGEN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; COMBRETASTATIN A4 PHOSPHATE; GLYCERYL TRINITRATE; MORPHINE; PACLITAXEL; PLATINUM COMPLEX; TAXANE DERIVATIVE;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; ATAXIA; BLOOD TOXICITY; CANCER GRADING; CANCER PAIN; CHEST TIGHTNESS; CLINICAL ARTICLE; CONFUSION; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FLUSHING; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HEART RATE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTENSION; INFECTION; INJECTION SITE PRURITUS; LYMPHOCYTOPENIA; MOOD DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE CRAMP; NEUROLOGIC DISEASE; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OVARY ADENOCARCINOMA; OVARY CANCER; PARESTHESIA; PATIENT CONTROLLED ANALGESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; QT PROLONGATION; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SKIN MANIFESTATION; SKIN TINGLING; STOMATITIS; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; THROMBOCYTOPENIA; TUMOR GROWTH; UPPER RESPIRATORY TRACT INFECTION; VOMITING;

EID: 79953648492     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq708     Document Type: Article

References (29)

1. American Cancer Society. Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society 2010.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
3. Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol 2005; 17: 399-411.
4. The International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002; 360: 505-515.
5. Bookman MA, Brady MF, McGuire WP et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol 2009; 27: 1419-1425.
6. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
7. Markman M, Reichman B, Hakes T et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991; 9: 1801-1805.
8. ten Bokkel Huinink W, Gore M, Carmichael J et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 1997; 15: 2183-2193.
9. Gordon AN, Tonda M, Sun S et al. Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 2004; 95: 1-8.
10. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009; 100: 1-7.
11. Patterson DM, Rustin GJ. Vascular damaging agents. Clin Oncol 2007; 19: 443-456.
12. Pettit GR, Singh SB, Niven ML et al. Isolation, structure, and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nat Prod 1987; 50: 119- 131.
13. Rustin GJ, Galbraith SM, Anderson H et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003; 21: 2815-2822.
14. Dowlati A, Robertson K, Cooney M et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002; 62: 3408-3416.
15. Stevenson JP, Rosen M, Sun W et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003; 21: 4428-4438.
16. Bilenker JH, Flaherty KT, Rosen M et al. Phase I trial of combretastatin A-4 phosphate with carboplatin. Clin Cancer Res 2005; 11: 1527-1533.
17. Rustin GJ, Shreeves G, Nathan PD et al. A phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. Br J Cancer 2010; 102: 1355-1360.
18. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
19. Rustin GJ. Use of CA-125 to assess response to new agents in ovarian cancer trials. J Clin Oncol 2003; 21: 187-193.
20. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1-10.
21. Cooney MM, Radivoyevitch T, Dowlati A et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004; 10: 96-100.
22. Markman M, Rothman R, Hakes T et al. Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 1991; 9: 389-393.
23. Vasey PA, Jayson GC, Gordon A et al. Phase III randomized trial of docetaxelcarboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 2004; 96: 1682-1691.
24. Ferrandina G, Ludovisi M, Lorusso D et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol 2008; 26: 890-896.
25. Monk BJ, Herzog T, Kaye SB et al. A randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) vs PLD in relapsed, recurrent ovarian cancer (OVA-301). ESMO Conference, Stockholm 2008.
26. Vergote I, Finkler N, del Campo J et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009; 45: 2324-2332.
27. Sharma R, Graham J, Mitchell H et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer 2009; 100: 707-712.
28. Cadron I, Leunen K, Amant F et al. The "Leuven" dose-dense paclitaxel/ carboplatin regimen in patients with recurrent ovarian cancer. Gynecol Oncol 2007; 106: 354-361.
29. Katsumata N, Yasuda M, Takahashi F et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009; 374: 1331-1338.